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At present there is considerable evidence that the patho-
logic processes in the nephritis of systemic lupus erythema-
tosus (SLE) are mediated at least in part by immunological
mechanisms 1—7]. The deposition of immune complexes in
the glomeruli in this disease and the subsequent injury that
ensues bear a resemblance to the nephritis in the experi-
mental serum sickness animal models. The immunological
and phlogistic events following the injection of a single
foreign antigen have been defined to a considerable degree
in these models. However, it is well known that marked
variations in the frequency of induction and severity of the
nephritis occur in different animals because of individual
variations in the immune response [8, 9]. The situation in
human systemic lupus erythematosus is considerably more
complex since in man the immune response is certainly no
less variable, and it now appears that several antigen-anti-
body systems are involved in the pathogenesis of the renal
lesion.
It is the purpose of this paper to review some of the
serologic and renal biopsy studies that have helped to
delineate the heterogeneity of the immune complex systems
that appear to be important.
Immunofluorescent studies of renal biopsies. Morphologic
data obtained from immunofluorescence studies of renal
biopsies from a broad group of SLE patients suggest that
different immune complexes are involved in the nephritic
process (Table 1). Marked variations in the deposition of
y-globulin and complement can occur as indicated by the
presence of four distinct immunofluorescence patterns of
glomerular staining (Fig. 1). Linear staining appeared as
homogenous staining of the glomerular basement mem-
brane. Mesangial patterns were characterized by deposits
lying between loops that appeared to radiate from the
central portion of the glomerulus. Granular deposits ranged
in size and were distributed irregularly throughout the
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Fig. 1. Different patterns of fluorescence in four SLE biopsies.
A) Patient D. S.: linear deposits of yG-globulin along GBM.
B) Patient P. W.: mesangial deposits of y-globulin shown as
irregular strandlike areas of fluorescence lying between capillary
loops. C) Patient I. B.: granular deposits of y-globulin along
GBM. D) Patient M. R.: lumpy deposits of immunoglobulin
outlining tufts. All x 250.
glomerulus. Lumpy deposits of y-globulin outlined the
glomerular tufts obscuring the normal architecture. Linear,
granular or lumpy types of deposits were usually accom-
panied by mesangial deposits of immunoglobulin and
complement. Immunoglobulin and complement were ob-
served in similar distribution except in the case of the linear
staining pattern which was confined to yG-globulin. An
occasional renal biopsy with granular deposits showed very
few deposits in the mesangium.
Certain patterns of glomerular deposits appear to corre-
late with the presence of renal disease. Linear or mesangial
staining alone were found in kidneys without clinical or
Immune complex systems in lupus nephritis 91
Table 1. Clinical findings and renal biopsy immunofluorescent data in SLE patients
Renal biopsies
Serum
Duration (years) Prednisone
Protein
Pattern of depositeda Proteinuriab creatinine Total Renal Duration
Patient deposits yG yM fl1C g/24 hr mg/lOOmIc disease disease ing/day years°
I. MCK Membranous 2+ 0 0 0.10 0.9 10 — 2.5 7
2. SCH Membranous 3+ 0 0 0.20 0.9 3 — 50—*2.5 1
3. BER Mesangial 0 1+ 0 0.9 3 — 60—*10 I
4. GAM Mesangial 2+ 2+ 0 1.0 7 — 0 0
5. URA Mesangial 3+ 0 3+ 0.1 1.1 4 — 60—5 1
6. EGL Mesangial 2+ 2+ 0.1 0.7 2 — 120—*20 0.25
7. BAN Mesangial 3+ 1+ 3+ 0.31 1.0 6 — 0 0
8. WOL Mesangial 2+ 2+ 0.33 0.8 0.06 — 40 0.04
9. CIA Granular 2+ 2+ 2+ 0.8 1.2 12 12 Oe 0
10. ROS Granular 2+ 2+ 1.5 1.1 2 1 20—*2.5 0.25
11. HAU Granular 3+ 3+ 3+ 1.8 1.1 29 2 0 0
12. LOO Granular 2+ 0 2+ 2.2 0.8 1 0.5 60 0.06
13. WIL Granular 3 + 1 + 3 + 2.9 1.2 1 1 80 — 35 1
14. HAR Granular 3+ 2+ 2+ 3.1 1.2 9 0.17 5 — 10 6
15. FOR Granular 3+ 0 3+ 4.0 1.1 7 2 40—75 2
16. SAC Granular 3+ 1+ 3+ 4.4 1.4 1 0.25 40—* 15 0.25
17. MOR Granular 2+ 2+ 3+ 5.0 1.3 5 1 0 0
18. RUS Lumpy 1+ 3+ 3+ 7.6 1.6 12 2 60—+100 0.02
19. WEI Lumpy 3+ 2+ 8.3 2.3 2 2 10 1
a Graded as 0, neg; trace; 1+, minimal; 2+, moderate; 3+ marked.
b Upper limit for normals 0.4.
C Upper limit for normals 1.5.
histological evidence of glomerular injury. The linear
localization of y-globulin in SLE appears analogous to the
pattern of staining found in Goodpasture's syndrome [8];
however, the absence of associated complement deposition
and nephrotoxicity differentiate the two situations. Granular
deposits were associated with active glomerular nephritis,
while the lumpy pattern occurred with more advanced
histological and clinical renal disease.
Serologic studies. A summary of the wide variety of
antibodies to autologous tissue and plasma antigens that
occur in the serum of patients with SLE is shown in Table 2.
The antinuclear groups have received special study, which
initially was due primarily to their relationship to the LE
phenomenon and their striking appearance in fluorescence
antibody studies.
Antibodies to deoxyribonucleic acid were among the
earliest described [10, 2]. Subsequently antibodies to both
native (NDNA) and single-stranded determinants (SDNA)
have been extensively characterized [4, 11—23]. Antibodies
reactive with particulate and soluble nucleoprotein differ
from antiDNA antibodies with respect to the requirement
of a protein-DNA complex [24, 25]. Antibodies to two
soluble but distinct nuclear antigens have been described.
These have been partially characterized and are the Sm
antigen which is periodate-sensitive [26] and ENA which is
sensitive in part to both RNAse and trypsin f27, 28]. Anti-
bodies reactive with double-stranded RNA (DSRNA) have
Table 2. Antibodies in SLE sera
1. Antibodies to Nuclear Constituents
a. Native DNA
b. Single strand DNA
c. Nucleoprotein
d. "Carbohydrate-Protein" Antigens
Sm Antigen and Others
e. RNA-Protein (ENA)
II. Antibodies to Cytoplasmic Constituents
a. Ribosomes (RNAase sens.)
b. Carbohydrate Antigens
c. Lipid Antigens
III. Antibodies to Clotting Factors
IV. Red Cell Antibodies
V. Platelet Antibodies
VI. RNA Antibodies
Poly A Poly U
Poly I Poly C
Poly A
also been demonstrated and have received considerable
attention recently [29—31]. Antiribosomal antibodies have
been observed in association with renal disease [32], and a
variety of other anticytoplasmic antibodies have been found
in SLE sera in relatively low incidence [33, 34].
Recent extensive studies on the incidence of antibodies to
polynucleotides in human sera in different conditions [18]
' Duration of therapy prior to biopsy.
e 40—10 mg seven years, none for
three years prior to biopsy.
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have indicated that significant titers of antibodies to native
DNA are almost exclusively restricted to patients with SLE,
whereas antibodies to DSRNA preparations (Poly A
Poly U, Poly I Poly C) are sometimes found in sera from
patients with other diseases (Table 3). Antibodies to SDNA
occur more frequently than antibodies to NDNA in patients
with SLE but are also present in high incidence in other
disease states. Antibodies to ribonucleoproteins were limited
mainly to patients with SLE, rheumatoid arthritis and
mixed connective tissue disease.
Serial studies where antibody titers have been followed
during disease exacerbations have proven particularly in-
formative. An example is shown in Fig. 2. Antibody titers
to NDNA, SDNA, DSRNA and RNA-protein were
followed over 24 months. Two episodes of clinical activity
occurred during this period and were associated with rises
in antiNDNA antibody titers. Steroid treatment was asso-
ciated with clinical remission with a concomitant decrease
in antiNDNA antibody. Antibodies to SDNA were also
present during the first episode and persisted after clinical
symptoms abated. Antibodies to DSRNA appeared during
clinical quiescent periods. Antibodies to RNA-protein were
absent throughout the course. This example demonstrates
some of the common findings from a similar study of 25
patients followed over a period from six months to four
years. Peaks of activity of antibodies to NDNA, SDNA
and DSRNA generally occurred sometime during the course
of SLE in most patients, whereas antiribonucleoprotein
antibodies were completely absent from one-third of the
serial studies. Peaks of NDNA antibody appeared to
correlate better with disease activity and serum complement
depression than antibodies to SDNA or DSRNA. Anti-
bodies to ribonucleoprotein when present showed little
correlation with disease activity.
The P'JDNA-antiNDNA immune complex system. Anti-
bodies to NDNA in significant titers are restricted primarily
to patients with SLE and are useful from the diagnostic
iiiiiiiinL j Jun
standpoint, whereas antibodies to other nuclear antigens
studied occurred in patients with a variety of diseases.
Further indirect evidence for the special significance of
antibodies to NDNA arises from serial studies involving
serum complement determinations. Fig. 3 shows the close
inverse relationship between serum complement levels and
NDNA antibody titers which is frequently observed during
periods of disease activity in SLE patients [5, 35]. This
correlation occurs during periods of disease activity in
patients with and without renal disease as illustrated in
Figs. 3 and 4. Fig. 3 shows the serial study of a patient
whose episodes of clinical activity were characterized by
nephritis. A renal biopsy during one of these periods showed
deposits of y-globulin and complement in a granular pattern
along the glomerular basement membrane. In contrast, the
patient whose serial study is shown in Fig. 4 had similar
complement and DNA antibody findings but no clinical
nephritis. A renal biopsy in this case showed only mesangial
deposits.
The association of serum complement depression with
the presence of antiNDNA antibodies in the serum pro-
vides indirect evidence for NDNA-antiNDNA complex
formation. More direct evidence is provided by the de-
monstration of antigen in serum and in renal deposits.
NDNA in high concentrations has been demonstrated in
sera from SLE patients during periods of clinical exacer-
bation and was found to alternate with NDNA antibodies
[5, 53]. By using fluorescein-labeled antibody specific for
NDNA, NDNA has also been demonstrated in glomerular
deposits in a granular pattern similar to that of y-glohulin
and complement [6]. The NDNA was demonstrable after elu-
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Fig. 2. Serial study of patient J. R. showing the correlation of
periods of clinical activity (horizontal bars) with various poly-
nucleotide antibody levels in the serum. Antibody levels (vertical
bars) arc given in hemagglutiriation titers and expressed as log
base 2 on the ordinate [18].
Fig. 3. Serial study of patient S. V. showing two periods of
clinical exacerbations associated with increases in tiler of anti-
NDNA antibodies and serum complement depression. Antibodies
were assayed by agar gel precipitation, hemagglutination and
ammonium sulfate precipitation test using labeled DNA [36].
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Table 3. Incidence of antibodies to polynucleotides
Sera Antibodies positive, %
No.
Source Tested NDNA SDNA Poly A• Poly U Poly I Poly C RNA Pr
SLE 60 60 (7.3)a 87.0 (5.1) 55.0 (5.3) 21.6 (5.0) 66.6 (12.0)
Normal 110 0.3 (S.O)b 3.7 (4.0) 0 1.1 (4.0) 0
Hospitale 65 0 16.8 (4.3) 7.7 (4.1) 9.2 (4.3) 3.1 (9.0)
Procainamide 19 0 52.6 (4.5) 10.5 (6.0) 5.3 (7.0) 0
Chronic active hepatitis 43 2.3 (3.0) 58.2 (5.1) 27.2 (6.OY' Od
Infectious mononucleosis 20 0 40.0 (5.2) 10.0 (4.0) 5.0 (4.0) 0
Rheumatoid arthritise 32 3.1 (3.0) 59.5 (5.5) 3.0 (5.0) 0 15.5 (10.0)
Chronic glomerulonephritis 40 2.5 (4.0) 7.5 (4.6) 0 — 2.5 (9.0)
Primary biliary cirrhosis 20 0 15.0 (3.6) — — —
Carcinoma of cervix 13 0 0 0 0
a Mean titer of group of serums expressed as log base 2, shown in parenthesis.
b Two hundred eighty normal sera were tested.
Random hospital sera obtained from patients with a variety of diseases.
d Eleven sera were tested.
Two patients had clinical evidence of mixed connective tissue disease in addition to rheumatoid arthritis.
Table 4. Concentration of antibodies in glomerular eluates [36] The elution studies of isolated glomeruli from autopsy
kidneys have been one of the most informative avenues of
investigation in the study of SLE nephritis. The results
obtained in one such study [36] are shown in Table 4.
Eluates were prepared by treating glomeruli with 0.2 M,
pH 2.8 glycine buffer or desoxyribonuclease. Several types
of antibodies were eluted by both procedures. It was deter-
mined that certain types of antibodies were concentrated in
the glomeruli if the ratio of the antibody titer to the y-
globulin content in the eluate was greater than that for a
terminal serum specimen. Most eluates showed concen-
trations of antibodies directed against NDNA and SDNA.
Antiribonucleoprotein antibodies were also concentrated in
some eluates, but no antiDSRNA antibodies were found.
The SDNA-antiSDNA system. Antibodies to SDNA
occur in a variety of diseases associated with active tissue
destruction but the highest incidence occurs in patients
with SLE. Recently SDNA antigen also has been found in
the sera of a similar group of patients [37]. The highest
__________________________________
levels of SDNA were found in patients with SLE. This was
especially apparent when sera were assayed throughout the
course of the disease of individual patients (Table 5). The
mean serum concentration of SDNA in these serial studies
__________________________________
was 50 tg/ml and levels as high as 250 tg/ml were observed
1968 1969 in individual sera. SDNA alternated with the presence of
SDNA antibody in a fashion similar to that demonstrated
for the NDNA-antiNDNA system. In a number of sera
both SDNA and antibody to SDNA could be demonstrated.
In addition, evidence was presented that antiNDNA-
SDNA complexes can also occur in the sera of SLE patients.
The association of rising titers of antiSDNA antibody
with serum complement depression and clinical activity was
less prominent than that observed for antiNDNA anti-
bodies; however, SDNA antibodies frequently arose in
parallel with antiNDNA during periods of clinical activity.
Total
number
studied
Anti
NDNA
Anti
SDNA
Anti
RNA Pra
Acid buffer eluates 9 5b 6 3
Deoxyribonuclease
eluates 9 6 8 1
2Normal range —
1965 1966rn1967
a RNA Pr, ribonucleoprotein.
b Number of eluates with increased antibody activity per mg of
globulin in comparison with serum.
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Fig. 4. Serial study of patient D. W. showing two periods of
clinical exacerbations with systemic symptoms and renal disease.
Each episode is associated with an increased titer of antiNDNA
and serum complement depression [36].
tion of in vivo antibodies which blocked the in vitro reaction
of fluorescein-labeled antiNDNA antibodies. AntiNDNA
antibodies have been eluted from kidneys in which NDNA
has been demonstrated in glomerular deposits [6].
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Table 5. Incidence of SDNA antigen and antibody in serial studies
of SLE patients [37J
Duration No. of % of sera Mean conc. % of
Patient of study,
months
sera
tested
positive
for SDNA
antigen
of SDNA
antigen
(ag/mi)
in sera
sera
positive
for
SDNA
antibody
Wol 24 22 0 0 23
Loo 6 11 0 0 46
Esp 25 15 0 0 54
Garn 9 21 0 0 66
Har 22 24 0 0 42
\1ra 36 45 13 41.3 62
Bro 31 26 15 17.1 39
1-Iau 51 55 15 20.1 0
Ros 24 25 20 19.9 32
McK 16 19 21 15.2 37
For 24 24 25 19.1 54
EgI 31 34 28 22.2 21
Ber 16 28 29 18.2 32
Pea 17 24 33 25.9 83
Rus 31 40 48 65.4 32
Sil 13 15 60 111.8 27
Wil 34 22 64 125.4 27
Wei 10 20 90 52.6 20
More direct evidence that the SDNA-antiSDNA system
may play a role in the pathogenesis of nephritis in SLE is
the detection of both antigen and antibody in glomerular
deposits in diseased kidneys. Immunofluorescence studies
by Andres et al [38] have demonstrated that SDNA antigen
is deposited in glomeruli lesions of SLE kidneys in asso-
ciation with v-globulin and complement deposits, while
elution studies (Table 3) indicate that SDNA antibody is
selectively concentrated in glomeruli obtained from SLE
kidneys at autopsy.
Detection of immune complexes with Clq. The Clq com-
ponent of complement which is known to precipitate
soluble immune complexes [39] has recently been shown to
give precipitin reactions with aggregated v-globulin or
immune complexes in gel diffusion [40]. This method was
found useful in detecting high molecular weight complexes
containing y-globulins in hypocomplementemic sera from
SLE patients with active disease as shown in Fig 5 [40, 41].
A number of other types of low molecular weight materials
also have been detected in SLE sera by this method. Ap-
proximately 75 % of hypocomplementemic SLE sera tested
had Clq reactants which in the majority of cases could be
characterized as high or low molecular weight material,
while sera from inactive patients were uniformly negative.
The exact nature of these reactants is at present unknown.
Materials other than complexes of v-globulin can react with
Clq in gel diffusion; these include biologic polyanions such
as NDNA, SDNA, double-stranded and single-stranded
polyribonucleotides, heparin and endotoxin lipopoly-
saccharide, but these ordinarily can be differentiated from
Fig. 5. Gel diffusion plate showing the precipitation of isolated
Clq (well A) with two sera from patients with active SLE disease
and hypocomplementemia (wells I and 2). The sera from two
patients with inactive SLE are in wells 3 and 4.
y-globulin reactants by their persistence after reduction and
alkylation—a treatment which destroys the precipitability
of v-globulin complexes with Clq [40—44]. The high mole-
cular weight reactants are comprised mainly of yG-globu-
lins, although unidentified material is also present which
could possibly represent antigens of immune complexes
[41].
The low molecular weight complexes are also incomplete-
ly characterized. In isolated preparations of these reactants
yG-globulin is present [41]. However, recent experiments
indicate that material resistant to reduction and alkylation
appears to be involved in some cases. Also, pronase treat-
ment of the serum occasionally results in a Clq reactant
of smaller size. These findings raise the possibility that a
low molecular weight anionic substance, possibly of foreign
origin, may be involved directly or complexed to v-globulin.
The v-globulin--anti- v-globulin system. The correlation of
the occurrence of serum cryoglobulin precipitates with
periods of acute disease activity and especially nephritis
has been pointed out by Christian et al [45, 46]. In the
course of studies on Clq reactants in SLE sera it be-
came apparent that in some cases a relationship exists
between the presence of Clq precipitable complexes and
cryoprecipitates [41]. The course of one patient whose
episodes of disease activity correlated with the occurrence
of Clq precipitins and cryoprecipitates in the serum is
shown in Fig. 6. Two episodes of disease activity are shown.
During these periods Clq precipitins and cryoprecipitates
were present in the serum, associated with low serum com-
plement and the initiation of a nephritic process.
Isolation work on these precipitates has offered evidence
for unknown antigen-antibody complexes which interact
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Fig. 6. Serial study of an exceptional SLE patient (J. Al. H.)
showing two broad periods of clinical activity with renal disease
which were associated with the presence of cryoprecipirins and
Cl9 reactivity in the serum. No antibodies to polynucleotides
were present.
Fig 7. Serial studies on patient M. R. There are two periods of
clinical exacerbations with nephritis that were associated with
Clq reactants, cryoprecipitates and depressed serum comple-
ment. DNA antibodies were also present during these periods
[36].
Table 6. Serological and immunofluorescent findings in SLE patients with cryoprecipitins and Clq precipitin reactions
Cryoprecipitins
Clq
Renal biopsy
Rheumatoid Pattern of Proteinuria
mg/l/0 ml factor precipitation deposit yG yM RF g/24 hr
M. R. 36.8 + ++ Granular 3+ 3+ 2+ 4.8
J. M. H. 14.4 + --+-l- Granular 3+ 2+ Tr 5.7
J.H. 10.0 + ++ Granular 3+ 3+ 2+ 1.4
A.B.a 12.0 + ++ Granular 1+ 3+ 0 1.6
G. G. 2.8 0 ++ Mesangial 2+ Tr NSb 0
S. V. 3.6 0 ++ Mesangial 3+ 0 NS 0.1
D. S. 2.7 0 + Mesangial 3+ 0 NS 0
a with Sjogren's syndrome.
b NS—not studied.
1MB.
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with 1gM anti-y-globulins and Clq to form larger com-
plexes which appear to be of special significance. The
complexes that appear to be involved in this system are
similar to the high molecular weight type Clq reactants.
Low molecular weight CIq reactants present in SLE are not
reactive with anti- y-globulins, and while they are associated
with hypocomplementemia and clinical activity, they have
not thus far been implicated in the nephritic process [41].
Further evidence for the possible significance of the
'-globu1in—anti-y-g1obu1in system in the nephritic process
was obtained by serologic and renal biopsy studies on a
group of patients followed serially (Table 6). The first four
all had relatively large amounts of cryoprecipitates which
contained anti-y-globulins. These patients had significant
proteinuria and on renal biopsy showed heavy deposits of
yM in a granular pattern in their glomeruli. In three of the
biopsies anti-y-globulins were detected by staining with
fluorescein-labeled aggregated y-globulin. The last three
had smaller amounts of cryoprecipitates and no detectable
anti-y-globulins. These patients did not have significant
proteinuria or yM deposits. The deposits that were present
were of the more benign mesangial type.
Cryoglobulinemia in this situation appears to be an
in vitro manifestation of circulating complexes which in vivo
are deposited in the glomeruli. More direct evidence for
this was obtained by demonstrating that the same anti-y-
globulins were in the isolated cryoprecipitins and glomeru-
lar deposits. This was accomplished by staining the renal
deposits with fluorescein-labeled idiotypic antiserum to the
isolated anti-y-globulins [41, 541.
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This system appears to be independent of the DNA-
antiDNA system. It was noted in the studies on poly-
nucleotide antibodies that three of twenty-five patients did
not develop such antibodies during typical clinical courses of
SLE, although renal disease was observedintwoof the three
patients. The patient whose course is shown in Fig. 6 had
no evidence of antipolynucleotide antibodies. En addition,
one other (A. B.) of the four patients (Table 6) with similar
clinical and serologic findings to those shown in Fig. 6 did
not have any detectable DNA antibodies. In another
(Fig. 7), high-titered DNA antibodies occurred during
periods of disease activity. These antibodies did not appear,
however, to be related to the cryoprecipitins or Clq preci-
pitins also present, since they were not concentrated in
either of these precipitates and DNAse treatment of the
serum did not affect formation of the cryoprecipitins or
serum reactivity of Clq.
Discussion
The factors which determine the localization of com-
plexes to the glomerular basement membrane (GBM) are
incompletely understood. One possibility that arises from
the above studies is that there is a progressive renal depo-
sition of immunoglobulins and complement in the nephritis
of SLE which may be correlated closely with the clinical
course of the disease. The mesangium may be the initial site
of localization of complexes followed by granular deposits
along the basement membrane, and then, with advanced
nephritis, a coalescence of these deposits may occur with
formation of lumpy aggregates. There is some support for
this thesis. The mesangium is known to contain phagocytic
cells that represent a primary filtering agent of the kidney
[47]. It is conceivable then that deposition of immune com-
plexes on the GBM occurs only after saturation of the
mesangium. Also, the lumpy pattern found in patients with
more advanced nephritis is the one most frequently ob-
served in nephritic kidneys at necropsy [48]. On the other
hand in the present studies there was little correlation be-
tween the length of systemic disease and the type of deposit
in the renal biopsy studies.
The finding of occasional renal biopsies that show gran-
ular deposits but very few deposits in the mesangium
raises an alternative possibility that a qualitatively different
type of immune complex with strong affinity for the GBM
may be formed at certain stages of the disease and localize
primarily on the GBM without entering the mesangium.
From experimental evidence it is known that the size of the
complexes as determined by ratio of antigen to antibody,
and the presence of multivalent antigens, may influence the
site of glomerular localization of complexes [8, 49—51].
Another consideration may be the ability of the antigen to
activate complement. Certain biological antigens including
many polynucleotides are known to activate complement
[40—44]. The presence of both complement-activating an-
tigen and antibody may enhance the nephrotoxicity of such
complexes.
Linear localization of yG-globulin in glomeruli in SLE
appears to be a special situation and was observed in two
cases. The pattern of staining observed is analogous to that
observed for anti-basement membrane antibodies in Good-
pasture's syndrome but without concurrent localization of
complement and with no histological or clinical evidence
of glomerular damage. Also, there appears to be no sensi-
tization of the basement membrane for localization of anti-
y-globulins, since both patients had high-titer rheumatoid
factors at various times. On the contrary, the possibility
exists that the yG-globulin in these cases represents non-
nephrotoxic antibody because of either its inability to fix
complement, or more likely, the spacing of its specific
antigen on the GBM. The net effect then may be a protective
one.
One of the factors which is difficult to assess is the effect
of steroid therapy on glomerular deposits. From the data
presented here there was no apparent relationship between
therapy and pattern of staining. Experimental evidence,
however, indicates that steroids can prevent deposition of
immune complexes on the GBM and clinical nephritis in
the acute serum sickness model but only partially affect the
nephritis in a variable way in the chronic serum sickness
model [52]. Since in man SLE appears to have acute and
chronic periods of disease activity, the effect of steroids on
the deposition of complexes may depend on when they are
administered in the course of the disease.
A wide variety of antibodies to autologous antigens occur
in the serum of patients with SLE. The antibodies which
assume importance in relation to renal lesions are those
which may come in contact with antigens in the blood-
stream and form antigen-antibody complexes. Thus far
NDNA and SDNA have been the only antigens demon-
strated to occur in SLE sera in significant concentrations.
Undoubtedly others occur. Elution studies of isolated
glomeruli show concentrations of antiribonucleoprotein
antibodies in addition to NDNA and SDNA antibodies.
Antibodies to DSRNA, however, were not present. From
these studies, one may expect the occurrence of ribonucleo-
protein in the circulation.
A subject of considerable current interest is the source of
NDNA and SDNA in SLE sera. The finding of uniquely
high concentrations of SDNA appears particularly signi-
ficant. Most antiNDNA antibodies can also react with
SDNA [18], and SDNA-antiNDNA complexes have been
shown to occur in addition to the NDNA-antiNDNA and
SDNA-antiSDNA complexes. In contrast to NDNA, which
occurs in high concentrations in other disease states, the
highest concentrations of SDNA occur in SLE. Since high-
titered NDNA antibodies are unique to SLE, while SDNA
antibodies are not, the SDNA-antiNDNA system may be
of considerable importance. It remains to he determined if
the DNA present in renal lesions is predominantly native or
single-stranded.
Immune complex systems in lupus nephritis 97
The high concentrations of SDNA present in SLE sera
suggest that these antigens are mainly of host origin. It is
possible, however, that a portion of these are of exogenous
origin. The characterization of specificities of antibodies
present has not so far determined the source of circulating
antigens, since DNA antibodies are found to react similarly
with DNA from different species, lower organisms and
viruses [181. Further studies are needed to resolve this
point.
The "y-globulin—anti-y-globulin" system which is inde-
pendent of the DNA systems appears to involve undeter-
mined types of immune complexes that are detected in the
circulation by precipitation with Clq. In vivo these com-
plexes can interact with anti- y-globulins and complement
and deposit in tissues; in vitro this interaction is manifested
by "cryoglobulinemia. "Evidence that this system may play
a role in the nephritic process is provided by studies which
demonstrate the same anti-y-globulins in the patient's
cryoprecipitate and glomerular deposits by use of fluo-
rescein-labeled antibody with idiotypic specificity for the
anti- y-globul ins.
A large percentage of SLE patients have circulating
rheumatoid factors, and not all of these have nephritis. It
appears that circulating anti- y-globulins have a detrimental
effect in SLE patients only when circulating high molecular
weight complexes such as those precipitable by Clq are
also present. It remains possible, however, that specific
characteristics of the anti-y-globulins such as the affinity
coefficient or thermal reactivity may also play a primary
role. It is notable that in the patient in this study with the
most severe nephritis, the anti- y-globulins were of the cold
reactive type.
Several types of immune complexes appear to be involved
in the nephritis of SLE, and multiple types can occur in the
individual patient. From the accumulated evidence the
DNA-antiDNA complexes appear to be of major impor-
tance. However, the presence of these complexes does not
invariably result in clinical nephritis. Also, DNA antibodies
sometimes occur during periods of disease activity along
with Clq reactants and cryoprecipitins. At this point, it
cannot be determined which of these is the primary system
involved in the nephritis in such cases. The stimulus for the
formation of various antibodies and release of antigen in
SLE is not known. Recent studies have suggested viral
infection [55—59]; however, the evidence for this is sparse.
It is of interest that in NZB/NZW mice, nephritis can be
enhanced by various viral infections, but regardless of the
virus used, the antinuclear antibodies comprised the major
portion of the y-globulin eluted from the affected kidneys
of these animals, with specific antiviral antibodies making
up a significant but lesser amount [60]. Thesituationmay
be similar in human SLE. Immune complexes involving
polynucleotides may very well play the major role in the
renal disease. However, unknown antigens, some of them
perhaps detected as the unidentified Clq reactants, may be
of special etiologic significance.
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